Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Halozyme Therapeutics

Halozyme Therapeutics reported $74.26M in EBITDA for its fiscal quarter ending in March of 2023.

Ebitda Change
Acadia Pharmaceuticals ACAD:US USD -53158000 7.58M
Agios Pharmaceuticals AGIO:US USD -88823000 8.54M
Alnylam Pharmaceuticals ALNY:US USD -135742000 38.56M
Amgen AMGN:US USD 3B 42M
Baxter International BAX:US USD 733M 87M
Cara Therapeutics CARA:US USD -27592000 3.65M
Eli Lilly LLY:US USD 1.96B 528.3M
Esperion Therapeutics ESPR:US USD -48524000 6.1M
Halozyme Therapeutics HALO:US USD 74.26M 8.8M
Immunogen IMGN:US USD -41945000 17.19M
Intercept Pharmaceuticals ICPT:US USD -31543000 13.66M
Intra Cellular Therapies ITCI:US USD -48258000 1.03M
Ionis Pharmaceuticals IONS:US USD -110937000 93.44M
MannKind MNKD:US USD -3986000 3.71M
Minerva Neurosciences NERV:US USD -5341000 278K
Nektar Therapeutics NKTR:US USD -34714000 2.99M
Peregrine Pharmaceuticals PPHM:US USD 4.64M 5.5M
Pfizer PFE:US USD 8.01B 683M
United Therapeutics UTHR:US USD 297.7M 97.7M